Compare Glenmark Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 14.9 37.0 40.1% View Chart
P/BV x 2.4 4.1 60.1% View Chart
Dividend Yield % 0.4 0.4 104.0%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
CIPLA
Mar-19
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs712678 105.0%   
Low Rs484484 100.0%   
Sales per share (Unadj.) Rs349.6198.2 176.4%  
Earnings per share (Unadj.) Rs32.818.5 177.0%  
Cash flow per share (Unadj.) Rs44.335.0 126.7%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.30.5 64.8%  
Book value per share (Unadj.) Rs198.6186.3 106.6%  
Shares outstanding (eoy) m282.17805.70 35.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.72.9 58.3%   
Avg P/E ratio x18.231.4 58.1%  
P/CF ratio (eoy) x13.516.6 81.2%  
Price / Book Value ratio x3.03.1 96.5%  
Dividend payout %6.116.2 37.7%   
Avg Mkt Cap Rs m168,625468,031 36.0%   
No. of employees `00012.022.6 53.2%   
Total wages/salary Rs m20,56128,565 72.0%   
Avg. sales/employee Rs Th8,196.07,053.1 116.2%   
Avg. wages/employee Rs Th1,708.11,261.5 135.4%   
Avg. net profit/employee Rs Th768.5659.1 116.6%   
INCOME DATA
Net Sales Rs m98,655159,710 61.8%  
Other income Rs m2,0814,766 43.7%   
Total revenues Rs m100,736164,475 61.2%   
Gross profit Rs m15,85830,973 51.2%  
Depreciation Rs m3,25913,263 24.6%   
Interest Rs m3,3461,684 198.7%   
Profit before tax Rs m11,33520,791 54.5%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7565,695 66.0%   
Profit after tax Rs m9,25014,924 62.0%  
Gross profit margin %16.119.4 82.9%  
Effective tax rate %33.127.4 121.0%   
Net profit margin %9.49.3 100.3%  
BALANCE SHEET DATA
Current assets Rs m66,968124,266 53.9%   
Current liabilities Rs m40,21137,715 106.6%   
Net working cap to sales %27.154.2 50.0%  
Current ratio x1.73.3 50.5%  
Inventory Days Days8391 92.0%  
Debtors Days Days8195 85.6%  
Net fixed assets Rs m33,322105,190 31.7%   
Share capital Rs m2821,611 17.5%   
"Free" reserves Rs m55,770148,511 37.6%   
Net worth Rs m56,052150,123 37.3%   
Long term debt Rs m35,73838,301 93.3%   
Total assets Rs m132,888239,633 55.5%  
Interest coverage x4.413.3 32.9%   
Debt to equity ratio x0.60.3 249.9%  
Sales to assets ratio x0.70.7 111.4%   
Return on assets %9.56.9 136.8%  
Return on equity %16.59.9 166.0%  
Return on capital %17.811.8 150.5%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99857,410 109.7%   
Fx outflow Rs m22,85919,041 120.0%   
Net fx Rs m40,14038,368 104.6%   
CASH FLOW
From Operations Rs m13,24216,911 78.3%  
From Investments Rs m-6,990-16,687 41.9%  
From Financial Activity Rs m-7,387-3,487 211.8%  
Net Cashflow Rs m-2,971-3,451 86.1%  

Share Holding

Indian Promoters % 48.3 16.0 301.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 6.9 12.2 56.6%  
FIIs % 34.4 23.7 145.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   56,727 161,166 35.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  WYETH  TORRENT PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 127 Points Higher; Auto Stocks Witness Huge Buying(Closing)

Share markets in India continued to trade on a positive note during closing hours today and ended their session marginally higher.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 23, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS